

OVERALL PERFORMANCE

55%

# Teva Pharmaceutical Industries Ltd

Generic medicine manufacturer

Stock exchange: NYSE • Ticker: TEVA • HQ: Tel Aviv, Israel • Employees: 37,000


## PERFORMANCE IN THE 2026 BENCHMARK

**Mid-performing.** Teva performs well in Responsible Manufacturing, reporting partial compliance with discharge limits achieved at its own and suppliers' sites. It is mid-performing in Appropriate Access & Stewardship. It shows strong stewardship across its business practices and performs well in mitigating stockouts and shortages of its products in LMICs. However, it registers its products in fewer countries than other assessed generic medicine manufacturers and has product-specific access and stewardship strategies for just three of its 10 products assessed.

### How Teva was evaluated



### How score was achieved



## OPPORTUNITIES FOR TEVA

**Expand appropriate access to its antibacterial and antifungal medicines.** Teva has access strategies for only three of its ten medicines assessed and registers them, on average, in only three LMICs. It can expand access to its medicines by registering them more widely and/or implementing appropriate access strategies in LMICs. For example, for its Reserve antibiotic, linezolid, it can expand access beyond the one country where it is currently registered, prioritising countries with a high unmet need.

**Strengthen its governance of interactions with healthcare professionals and improve transparency.** Through its public policy governing interactions with healthcare professionals (HCPs), Teva already ensures that such interactions are based on a legitimate need and that transfers of value (ToVs) are made at fair market value. Teva can strengthen its policy, and thereby address appropriate use of its antimicrobials, by including provisions to mitigate potential conflicts of

interest – specifically between employees and HCPs – and setting limits on ToVs. It can also publicly disclose ToV information in more countries, including in those where this is not mandated by law or, if applicable, other codes of practice.

**Ensure compliance with discharge limits directly in wastewater and improve transparency on levels of compliance achieved by its suppliers.** Teva reports 73% compliance with discharge limits set in the receiving environment for its own sites, based on mass balance estimations and ~17% compliance for its suppliers' sites, but publicly discloses only its own site compliance. To further safeguard AMR risk from antibacterial manufacturing, it can publicly report compliance with discharge limits directly in wastewater for all its own and suppliers' sites – a step beyond its current practice of setting discharge limits in receiving water – in line with the 'stringent' WHO guidance.

## CHANGES SINCE NOVEMBER 2023 UPDATE REPORT ON PREVIOUS BENCHMARK OPPORTUNITIES

- In 2023, Teva was one of the first two companies to obtain the BSI Kitemark™ for Minimized Risk of AMR Certification. As of 2025, Teva has earned two Certifications.
- Since 2025, Teva has partnered with Clarivate to increase appropriate antimicrobial prescribing in Kenya through the launch of a digital stewardship programme targeted to physicians and patients.
- Responding to a 2021 AMR Benchmark opportunity, Teva showed progress in the number of sites with safe discharge levels of antibiotics, with 73% of sites meeting these standards in 2024 (up from 31% in 2021 and 64% in 2022).

# Teva Pharmaceutical Industries Ltd

## SALES AND OPERATIONS


**Therapeutic areas:** Analgesics, cardiovascular, gastroenterology, immunology, migraine, neurodegenerative, neuropsychiatry, oncology, respiratory diseases

**Product categories:** Consumer health products, generic medicines & biosimilars

**Investments in AMR:** In 2021, Teva committed to invest USD 8mn over 10 years in the AMR Action Fund and had contributed approximately USD 1.2mn as of 2024.

**M&A news:** None identified in the antibacterial and/or antifungal sectors.


Revenue by geographic region – USD



## SAMPLE OF PORTFOLIO ASSESSED BY THE BENCHMARK

### PORTFOLIO for diseases in scope

#### 105 products in Teva's anti-infective portfolio



#### 10 products selected for analysis

amoxicillin (A), amoxicillin/clavulanic acid (A), azithromycin (W), ciprofloxacin (W), fosfomycin (R), linezolid (R), levofloxacin (T), moxifloxacin (T)

clotrimazole (F), fluconazole (F)

Key:  
A - Access antibiotic, W - Watch antibiotic, R - Reserve antibiotic, F - Antifungal medicine, T - Antituberculosis medicine

## PERFORMANCE BY RESEARCH AREA

### RESPONSIBLE MANUFACTURING

Indicators evaluated

B.1  
●  
B.2  
●

**Performs well.** Reports a comprehensive environmental risk-management strategy aimed at mitigating AMR risk at both its own and suppliers' sites. It reports on the level of compliance achieved at both its own and suppliers' sites. Teva also incorporates AMR provisions into supplier contracts. It publicly reports the quantification methods implemented and the level of compliance achieved at its own sites, but not at its suppliers'.

**Mitigates AMR risk at both its own sites and suppliers' sites; tracks compliance of antibacterials with discharge limits.** Teva's comprehensive environmental risk management strategy is based on the AMR Industry Alliance Antibiotic Manufacturing Standard (Industry Standard). Teva estimates antibacterial discharges at its own sites using mass balance, verified by chemical analysis. However, the underlying details (e.g., dilution factors, timeframe) are not disclosed. Teva reviews the antimicrobial discharge level quantification programme implemented at its own sites every five years and implements CAPA plans if PNECs are exceeded (e.g., increased dry-cleaning and collection of rinse water

for offsite incineration). While product-level compliance isn't reported, Teva states 19 of its 26 own manufacturing sites meet PNECs in the receiving environment, where wastewater is already diluted, which means that AMR risks present in wastewater may not be fully captured. It has also received five BSI Kitemark™ certifications for formulations of azithromycin and sulfamethoxazole-trimethoprim. Teva requires suppliers to follow the Industry Standard. It reviews supplier discharge levels via questionnaires and incorporates AMR provisions into contracts. It reports that 16 out of 97 supplier manufacturing sites comply with PNECs in the receiving environment. Each manufacturing site

works with external waste treatment plants and employs measures to treat wastewater prior to sending it to plants.

**Publicly discloses comprehensive AMR mitigation strategy, with 73% compliance for its own sites and tracks compliance at its suppliers' sites.** Teva publicly reports implementing the Industry Standard and quantifying discharge levels using mass balance estimation. It reports achieving compliance with discharge limits at 73% of its own sites and tracking PNEC compliance for its suppliers' sites. For both its own sites and its suppliers' sites, it does not publicly disclose the number of products complying with PNECs, measured discharge levels, or the names and locations of manufacturing sites for each antibacterial product.

\*Commencing January 1, 2024, Canada is reported under International Markets segment and is no longer included as part of United States segment (this is the case for both 2023/2024 figures). Could not


obtain reclassified data from 2021-2022). Revenue by business segment is reported per region as depicted in Turnover by geographic region figure, above.

# Teva Pharmaceutical Industries Ltd

APPROPRIATE ACCESS & STEWARDSHIP	Indicators evaluated	C.1.1	C.1.2	C.1.3	C.2.1	C.2.2	C.2.3	C.3	C.4	C.5
		●	●	●	●	●	●	●	●	●

**Mid-performing.** Shows strong performance in stewardship by clearly considering appropriate use across its business practices. It also performs well in ensuring continuous supply, as it has a comprehensive approach to mitigate stockouts and shortages and ensures GMP compliance at all its own and at several suppliers' sites. However, Teva can improve its registration coverage and implementation of access and stewardship strategies. While it has a portfolio-wide approach to expanding access and stewardship, it only reports product-specific strategies for three out of ten products assessed.

**Teva registers its off-patent medicines in fewer countries than its peers.**



Teva registers its off-patent medicines in 3 countries.\* In many countries where Teva registers its off-patent medicines, it also registers paediatric formulations. Its Reserve antibiotics and medicines targeting MDR-TB are registered in 2 countries, including a total of 1 country where the corresponding disease burden is high. Teva does not report engaging in any mechanism to facilitate registrations for the products selected for analysis.

**Below-average performance, with limited evidence of implementing access and stewardship strategies for 3 of 10 off-patent/generic products assessed.** Teva provides evidence of

access strategies for only 3 products – amoxicillin, azithromycin and amoxicillin/clavulanic acid – and no stewardship strategies for any of them. However, Teva does have general access-to-medicine and stewardship policies in place that apply across its portfolio. Amoxicillin, azithromycin and amoxicillin/clavulanic acid are donated through different NGO partners, such as Direct Relief International, to a number of countries, including Haiti, Senegal and the Dominican Republic, respectively. The company reports the number of doses donated in these countries. While Teva does not report any stewardship strategies tailored to the products assessed, the company implements responsible promotion and sales practices for all its antibacterial and antifungal medicines.

**Strong efforts to mitigate stockouts/shortages. Some reported evidence of systems to ensure product quality.** Teva implements demand planning and data sharing by using a monthly rolling forecast with a 36-month horizon. The plan is shared with key internal stakeholders annually. Teva does not report sharing forecasts with external stakeholders. It maintains buffer stocks of critical APIs and finished products and operates an automated inventory management

system that provides real-time data and demand forecasts to trigger replenishment. Its supplier diversification strategies implement dual sourcing for certain products, as well as local sourcing. Teva mitigates substandard and falsified medicines by verifying suppliers through GMP audits, reporting cases to relevant authorities, assisting in the identification of counterfeit products and training local officials to recognise them. It reports that 48/48 of its own sites are GMP compliant, but it is unclear how many of its 41,000 suppliers are GMP compliant. It also does not implement additional quality measures in countries with evolving regulatory systems.

**Clearly addresses appropriate use across its business practices.** Teva does not deploy sales agents to sell and/or promote its antibacterial and antifungal medicines to HCPs. Through its global public policy, Teva ensures all interactions with HCPs are ethical by specifying the legitimate need for such interactions. It also ensures that transfers of value (ToVs) are made at fair market value. While Teva abides by disclosure requirements, it does not voluntarily disclose ToVs publicly in countries where it is not mandated to by law, or by other codes of practice. Teva's public policy also applies to third parties working on its behalf.

\*All numbers in this statement are expressed as an **average** of the products selected for analysis and refer to registrations in the 113 countries in scope for 'access metrics'.